Clinical trials: Operable Breast Neoplasms
Untreated Operable Early Breast Cancer
Randomized Phase II Study to Assess PD 0332991 in Breast Cancer
This is a Phase II study trying to identify whether short term treatment with PD0332991 yields anti-proliferative response -defined by a low level of Ki67 expression (IHC) at surgery- or induces senescence as determined by SABG…
- Trial name
- POP (NCT02008734)
- Testing
- PD0332991
- Where
- France
- Volunteers
- 132 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
HER2-positive Breast Cancer, Operable Breast Cancer
Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer
First preclinical data suggest that pegfilgrastim could constitute a potent adjuvant for immunotherapy with mAb possessing ADCC/ADCP properties as trastuzumab.
- Trial name
- BREASTIMMU02 (NCT03571633)
- Testing
- Trastuzumab + Paclitaxel, Pegfilgrastim
- Where
- 9 sites in France
- Volunteers
- 90 people
- Sponsor
- Centre Leon Berard
Breast Neoplasms
A Safety and Tolerability Study of Assisted and Self-Administered Subcutaneous (SC) Herceptin (Trastuzumab) as Adjuvant Therapy in Early Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
This multicenter, two-cohort, non-randomized, open-label study will evaluate the safety and tolerability of assisted and self-administered SC Herceptin as adjuvant therapy in participants with early HER2-positive breast cancer…
- Trial name
- SafeHER (NCT01566721)
- Testing
- Herceptin
- Where
- 437 sites in Albania, Algeria and 57 more
- Volunteers
- 2,577 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
6xFU/Epirubicin/Cyclophosphamide (FEC) Compared to 3xFEC-3xDocetaxel in High-risk Node-negative Breast Cancer Patients
In low-risk node-negative breast cancer patients adjuvant chemotherapy should be spared. The identification of this subgroup can be based either on clinical and pathological or on tumour-biological criteria.
- Trial name
- NNBC3-Europe (NCT01222052)
- Testing
- 5-Fluorouracil, Epirubicin, Cyclophosphamide, Docetaxel
- Where
- Germany
- Volunteers
- 4,150 people
- Sponsor
- Martin-Luther-Universität Halle-Wittenberg
Breast Cancer
EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer
This is a prospective, randomised phase III trial, to compare the efficacy and safety profiles of two types of adjuvant chemotherapy regimens for human epidermal growth factor receptor 2 (HER2) negative, node positive breast…
- Trial name
- NCT00129935
- Testing
- Docetaxel, Capecitabine, Epirubicin
- Where
- 58 sites in Spain
- Volunteers
- 1,384 people
- Sponsor
- Spanish Breast Cancer Research Group
TNBC - Triple-Negative Breast Cancer
A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer
This review will evaluate the efficacy and safety of SHR1210 (Camrelizumab) and antivascular drug(Famitinib) in combination with anthracyclines/taxane-based adjuvant chemotherapy (carrelizumab + FAM + EC-P) compared with…
- Trial name
- NCT05862064
- Testing
- epirubicin,cyclophosphamide,paclitaxel,Carrelizumab, epirubicin,cyclophosphamide,paclitaxel
- Where
- China
- Volunteers
- 606 people
- Sponsor
- Fudan University
Breast Cancer
Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if chemotherapy given before surgery is more effective with or without docetaxel given…
- Trial name
- NCT00002707
- Testing
- Cyclophosphamide, Docetaxel, Doxorubicin
- Where
- 145 sites in United States, Canada
- Volunteers
- 2,411 people
- Sponsor
- NSABP Foundation Inc
Breast Cancer
Studying Tumor Samples From Women Who Have Undergone Chemotherapy for Breast Cancer
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00897845
- Testing
- RNA analysis, microarray analysis, immunohistochemistry staining method
- Volunteers
- 2,541 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Breast Cancer
Efficacy and Safety With Albumin-bound Paclitaxel (Abraxane) in the TAC as Neoadjuvant Chemotherapy in Breast Cancer
Select 60 cases of women with breast cancer at clinical stage of T1-4N0-2M0. Then treat them with 4 cycles of TAC (Abraxane 260mg/m2,EPI 60 mg/m2 ,CTX 500 mg/m2, 21day/cycle) as neoadjuvant chemotherapy.
- Trial name
- NCT01647672
- Testing
- Abraxane
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Tianjin Medical University
Breast Cancer
Tamoxifen With or Without Combination Chemotherapy in Treating Postmenopausal Women With Operable Invasive Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using tamoxifen may fight breast cancer by blocking the uptake of estrogen.
- Trial name
- NCT00002581
- Testing
- cyclophosphamide, fluorouracil, methotrexate
- Where
- 9 sites in United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- Scottish Cancer Therapy Network
Chemotherapy-Related Cognitive Impairment, Breast Cancer
GM1 Prophylaxis for Post-chemotherapy Cognitive Impairment in Patients With Early Operable Breast Cancer
The purpose of this study is to evaluate the prophylactic effects of Ganglioside-Monosialic Acid in post-chemotherapy cognitive impairment in patients with early operable breast cancer.
- Trial name
- NCT05239663
- Testing
- Ganglioside-Monosialic Acid, 250ml normal saline (NS)
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Sun Yat-sen University
Breast Cancer Female, Hormone Receptor Positive Malignant Neoplasm of Breast
Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer
The study is a randomized, double blind, placebo controlled, Phase 3 clinical trial with the primary objective of demonstrating the efficacy of palbociclib in combination with Endocrine therapy over Endocrine therapy alone…
- Trial name
- NCT03969121
- Testing
- Palbociclib, Endocrine therapy
- Where
- 25 sites in Australia, Hong Kong and 3 more
- Volunteers
- 141 people
- Sponsor
- Kyoto Breast Cancer Research Network
Breast Cancer
Neoadjuvant Phase II Trial in Patients With T1c Operable, HER2-positive Breast Cancer According to TOP2A Status
The main objective of this multicenter study will therefore be to evaluate pathologic complete response rates of an anthracycline-based regimen [FEC 100 - TAXOTERE® - HERCEPTIN® - PERTUZUMAB] and a non anthracycline-based regimen…
- Trial name
- NeoTOP (NCT02339532)
- Testing
- FEC100, Docetaxel, Trastuzumab
- Where
- 12 sites in France
- Volunteers
- 86 people
- Sponsor
- UNICANCER
Breast Cancer
ICI 182780 in Treating Women With Stage I or Stage II Primary Breast Cancer
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Hormone therapy using ICI 182780 before surgery may block the uptake of estrogen by the tumor cells and prevent metastases.
- Trial name
- NCT00010153
- Testing
- fulvestrant, conventional surgery
- Where
- United Kingdom
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Lung Cancer, Breast Cancer
Cambridge Brain Mets Trial 1
Proof of principle phase 1b / randomised phase 2 study of afatinib penetration into cerebral metastases for patients undergoing neurosurgical resection, both with and without prior low-dose, targeted radiotherapy.
- Conditions
- Lung Cancer, Breast Cancer, Brain Cancer, Advanced Breast Cancer
- Trial name
- CamBMT1 (NCT02768337)
- Testing
- Afatinib, 2 Gy targeted radiotherapy, 4 Gy targeted radiotherapy
- Where
- 6 sites in United Kingdom
- Volunteers
- 26 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Breast Neoplasm Female
Evaluation of ATRA Activity in Combination With Anastrozole in Pre-operative Phase of Operable Early Breast Cancer
This is an Italian, single center, randomized, phase II study. ATRA (all-trans retinoic acid) and derivatives (retinoids) are promising anticancer agents and exert their anti-proliferative, differentiating and apoptotic effects…
- Trial name
- ATRA (NCT04113863)
- Testing
- all-trans retinoic acid, Anastrozole 1mg
- Where
- 2 sites in Italy
- Volunteers
- 76 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Breast Cancer
Trial Comparing the Effects of Linear Versus Nonlinear Aerobic Training in Women With Operable Breast Cancer
The purpose of this study is to compare the effects of 3 different approaches to exercise training in women with early stage breast cancer who have completed all primary treatments (except hormone therapy, if appropriate).
- Trial name
- Excite (NCT01186367)
- Testing
- Linear Aerobic Training, Nonlinear Aerobic Training, Progressive Stretching
- Where
- United States
- Volunteers
- 174 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer
Bevacizumab in Combination With Chemotherapy in the Neo-adjuvant Setting for HER2 (-) Breast Cancer
Investigators propose to study the efficacy of Bevacizumab plus systemic chemotherapy prior to surgery in order to make a locally advanced tumor operable.
- Trial name
- NCT01985841
- Testing
- Bevacizumb, 5-Fluorouracil, Epirubicin
- Where
- 6 sites in Greece
- Volunteers
- 34 people
- Sponsor
- Hellenic Oncology Research Group
Breast Cancer
Combination Chemotherapy in Treating Women With Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003679
- Testing
- cyclophosphamide, docetaxel, doxorubicin hydrochloride
- Where
- United Kingdom
- Volunteers
- 350 people
- Sponsor
- Scottish Cancer Therapy Network
Carcinoma Breast Stage I, HER2 Positive Breast Cancer
Pre Operative Trastuzumab in Operable Breast Cancer
Background Information and Rationale: Trastuzumab is a humanized monoclonal antibody that acts extracellularly on the erbB-2 receptor.Trastuzumab is a recombinant humanized IgG1 monoclonal antibody against the human epidermal…
- Trial name
- NCT01785420
- Testing
- Trastuzumab
- Where
- India
- Volunteers
- 1,100 people
- Sponsor
- Dr Rajendra A. Badwe